Phase-Change nanoparticles using highly volatile perfluorocarbons: Toward a platform for extravascular ultrasound imaging

Theranostics

Volumn 2, Issue 12, 2012, Pages 1185-1198

  Matsunaga, Terry O ^a   Sheeran, Paul S ^b   Luois, Samantha ^c   Streeter, Jason E ^b   Mullin, Lee B ^b   Banerjee, Bhaskar ^c   Dayton, Paul A ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b USA and North Carolina State University   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Acoustic droplet vaporization; Diagnostic; Extravascular imaging; Perfluorocarbon; Phase change nanoparticles; Therapeutic; Ultrasound

Indexed keywords

1 PALMITOYL 2 HYDROXY SN GLYCERO 3 PHOSPHOCHOLINE; 1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE N METHOXY(POLYETHYLENEGLYCOL) 2000; DIPALMITOYLPHOSPHATIDYLCHOLINE; FLUOROCARBON; MACROGOL 2000; NANOPARTICLE; PERFLUBUTANE; PERFLUOROPENTANE; UNCLASSIFIED DRUG;

ANALYTICAL PARAMETERS; ANATOMICAL VARIATION; BILE DUCT; BLOOD CLOT LYSIS; DIGESTIVE SYSTEM; DRUG DELIVERY SYSTEM; DRUG PENETRATION; ESOPHAGUS; GAS DIFFUSION; GENE DELIVERY SYSTEM; HUMAN; IMAGE ANALYSIS; MICROBUBBLE; MOLECULAR IMAGING; PANCREAS DUCT; REVIEW; SONOTHROMBOLYSIS; TUMOR ABLATION; TUMOR CELL; ULTRASOUND; VAPORIZATION;

ACOUSTIC DROPLET VAPORIZATION; DIAGNOSTIC; EXTRAVASCULAR IMAGING; PERFLUOROCARBON; PHASE-CHANGE NANOPARTICLES; THERAPEUTIC.; ULTRASOUND;

ANIMALS; DIAGNOSTIC IMAGING; FLUOROCARBONS; HUMANS; NANOPARTICLES; PHASE TRANSITION; ULTRASONICS; VOLATILIZATION;

EID: 84878541793     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.4846     Document Type: Review

References (82)

1. Gramiak R, Shah PM. Echocardiography of the aortic root. Invest Radiol. 1968; 3: 356-66.
2. Porter TR, Xie F. Transient myocardial contrast after initial exposure to diagnostic ultrasound pressures with minute doses of intravenously injected microbubbles. Demonstration and potential mechanisms. Circulation 1995; 92: 2391-5.
3. Wei K, Jayaweera AR, Firoozan S, et al. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation. 1998; 97: 473-83.
4. Chomas JE, Pollard RE, Sadlowski AR, et al. Contrast-enhanced US of microcirculation of superficially implanted tumors in rats. Radiology. 2003; 229: 439-46.
5. Miller DL, Thomas RM. Ultrasound contrast agents nucleate inertial cavitation in vitro. Ultrasound Med Biol. 1995; 21:1059-65.
6. Lawrie A, Brisken AF, Francis SE, et al. Microbubble-enhanced ultrasound for vascular gene delivery. Gene Ther. 2000; 7: 2023-7.
7. Tachibana K, Tachibana S. Albumin microbubble echo-contrast material as an enhancer for ultrasound accelerated thrombolysis. Circulation. 1995; 92: 1148-50.
8. Hernot S, Klibanov AL. Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv Rev. 2008; 60: 1153-66.
9. Gessner R, Dayton PA. Advances in molecular imaging with ultrasound. Mol Imaging. 2010; 9: 117-27.
10. Kircher HF, Willmann JK. Molecular Body Imaging: MR Imaging, CT, and US. Part I. Principles. Radiology. 2012; 263: 233-43.
11. Campbell RB. Tumor physiology and delivery of nanopharmaceuticals. Anticancer Agents Med Chem. 2006; 6: 503-12.
12. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci USA. 1998; 95: 4607-12.
13. Torchilin VP. Passive and active drug targeting: Drug delivery to tumors as an example. Handb Exp Pharmcol. 2010; 197: 3-53.
14. Quaia E. Contrast media in ultrasonography-basic principles and clinical applications. New York: Springer. 2005.
15. Streeter JE, Gessner R, Miles I, et al. Improving sensitivity in ultrasound molecular imaging by tailoring contrast agent size distribution: in vivo studies. Molecular imaging 2010; 9: 87-95.
16. Talu E, Hettiarachchi K, Zhao S, et al. Tailoring the size distribution of ultrasound contrast agents: possible method for improving sensitivity in molecular imaging. Mol Imaging. 2007; 6: 384-92.
17. Gorce JM, Arditi M, Schneider M. Influence of bubble size distribution on the echogenicity of ultrasound contrast agents: a study of SonoVue. Invest Radiol. 2000; 35: 661-71.
18. Martinez HP, Kono Y, Blair SL, et al. Hard shell gas-filled contrast enhancement particles for colour Doppler ultrasound imaging of tumors. Med Chem Comm. 2010; 1: 266-270.
19. Lee SJ, Schlesinger PH, Wickline SA, et al. Interaction of melittin peptides with perfluorocarbon nanoemulsion particles. J Phys Chem B. 2011; 115: 15271-9.
20. Behan M, O'Connell D, Mattrey R, et al. Perfluorooctylbromide as a contrast agent for CT and sonography: preliminary clinical results. Am J Roentgenol. 1993; 160: 399-405.
21. Lanza G, Winter P, Caruthers S, et al. Theranostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions. Angiogenesis. 2010; 13: 189-202.
22. Lanza GM, Wickline SA. Targeted ultrasonic contrast agents for molecular imaging and therapy. Progr Cardiovasc Dis. 2001; 44: 13-31.
23. Mattrey RF. Perfluorooctylbromide: a new contrast agent for CT, sonography, and MR imaging. Am J Roentgenol. 1989; 152: 247-52.
24. Xing Z, Wang J, Ke H, et al. The fabrication of novel nanobubble ultrasound contrast agent for potential tumor imaging. Nanotechnology. 2010; 21: 145607.
25. Dayton PA, Matsunaga TO. Ultrasound-Mediated Therapies Using Oil and Perfluorocarbon-filled Nanoparticles. In: Moos W.H and Barry S.E, eds. Drug Development Research. Hoboken, NJ: Wiley-Liss, Inc. 2006: 42-6.
26. Hendrickson GR, Lyon LA. Microgel Translocation Through Pores under Confinement. Angew Chem. 2010; 49: 2193-97.
27. Kripfgans OD, Orifici CM, Carson PL, et al. Acoustic droplet vaporization for temporal and spatial control of tissue occlusion: A kidney study. IEEE Trans Ultrason Ferroelectr Freq Cont. 2005; 52: 1101-10.
28. Zhang M, Fabiili ML, Haworth KJ, et al. Initial investigation of acoustic droplet vaporization in canine kidney. Ultrasound Med Biol. 2010; 36: 1691-703.
29. Sheeran PS, Dayton PA. Phase-change contrast agents for imaging and therapy. Curr Pharm Des. 2012; 18: 2152-65.
30. Apfel R. Activatable Infusable dispersions containing drops of a superheated liquid for methods of therapy and diagnosis. US Patent No.5,840,276. Nov 24, 1998.
31. Rapoport NY, Kennedy AM, Shea JE, et al. Controlled and targeted tumor chemotherapy by ultrasound-activated nanoemulsions/ microbubbles. J Cont Rel. 2009; 138: 268-76.
32. Rapoport NY, Efros AL, Christensen DA et al. Microbubble generation in phase-shift nanoemulsions used as anticancer drug carriers. Bubble Sci Eng Technol. 2009; 1: 31-39.
33. Quay SC. Phase shift colloids as ultrasound contrast agents. US Patent No.5,558,853. Sept. 24, 1996.
34. Kawabata KI, Sugita N, Yoshikawa H, et al. Nanoparticles with multiple perfluorocarbons for controllable ultrasonically induced phase shifting. Jpn J Appl Phys. 2005; 44: 4548-52.
35. Zhang P, Porter T. An in vitro study of a phase-shift nanoemulsion: a potential nucleation agent for bubble-enhanced HIFU tumor ablation. Ultrasound Med Biol. 2010; 36 : 1856-66.
36. Sheeran PS, Wong VP, Luois S, et al. Decafluorobutane as a phase-change contrast agent for low-energy extravascular ultrasound imaging. Ultrasound Med Biol. 2011; 37: 1518-30.
37. Kripfgans OD, Fowlkes JB, Miller DL, et al. Acoustic droplet vaporization for therapeutic and diagnostic applications. Ultrasound Med Biol. 2000; 26: 1177-89.
38. Reznik N, Williams R, Matsuura N, et al. Perfluorocarbon nanodroplets for extravascular contrast. In The 17th Annual Symposium on Ultrasound Contrast Agents; Jan.19-20, 2012. Rotterdam: The Netherlands.
39. Martz TD, Bardin D, Sheeran PS, et al. Microfluidic Generation of Acoustically Active Nanodroplets. Small 2012; 8: 1876-9.
40. Giesecke T, Hynynen K. Ultrasound-mediated cavitation thresholds of liquid perfluorocarbon droplets in vitro. Ultrasound Med Biol. 2003; 29: 1359-65.
41. Kabalnov, A. Ostwald ripening and related phenomena. J Disp Sci Tech. 2001; 22: 1-12.
42. Sirsi SR, Chen CC, Feshitan JA, et al. Development of "Bulky" Lipid Microbubbles for Ultrasound Triggered Drug Delivery. Nashville, TN: AIChE Annual Meeting. 2009.
43. Sheeran PS, Luois S, Dayton PA, et al. Formulation and acoustic studies of a new phase-shift agent for diagnostic and therapeutic ultrasound. Langmuir 2011; 27: 10412-20.
44. Feshitan JA, Chen CC, Kwan JJ, et al. Microbubble size isolation by differential centrifugation. Journal of Colloid and Interface Science, 2009; 329: 316-24.
45. Reznik N, Williams R, Burns PN. Investigation of Vaporized Submicron Perfluorocarbon Droplets as an Ultrasound Contrast Agent. Ultrasound Med Biol. 2011; 37: 1271-9.
46. Lundgren CE, Bergoe GW, Tyssebotn I. The theory and application of intravascular microbubbles as an ultra-effective means of transporting oxygen and other gases. Undersea Hyperb Med. 2004; 31: 105-6.
47. Lundgren CE, Bergoe GW, Tyssebotn IM. Intravascular fluorocarbon- stabilized microbubbles protect against fatal anemia in rats. Artif Cells Blood Subst Immobil Biotechnol. 2006; 34: 473-86.
48. Lundgren C, Bergoe G, Olszowka A, et al. Tissue nitrogen elimination in oxygen-breathing pigs is enhanced by fluorocarbon-derived intravascular micro-bubbles. Undersea Hyperb Med. 2005; 32: 215-26.
49. Reznik N, Seo M, Williams R, et al. Optical studies of vaporization and stability of fluorescently labeled perfluorocarbon droplets. Phys Med Biol. 2012; 57: 7205-17.
50. Prosperetti, A. Bubble phenomena in sound fields. Part one. Ultrasonics. 1984; 22: 69-78.
51. Sheeran PS, Luois SH, Mullin LB, et al. Design of ultrasonically- activatable nanoparticles using low boiling point perfluroocarbons. Biomaterials. 2012; 33: 3262-9.
52. Klibanov AL, Microbubble contrast agents: targeted ultrasound imaging and ultrasound-assisted drug-delivery applications. Invest Radiol. 2006; 41: 354-62.
53. Sheeran PS, Streeter JE, Mullin LB, et al. Ultrasound Molecular Imaging with Customizable Nanoscale Phase-Change Contrast Agents: An In-Vitro Feasibility Study. IEEE International Ultrasonics Symposium (IUS) Proceedings. October 7-10, 2012; Dresden Germany.
54. Sheeran PS, Streeter JE, Mullin LB et al. Toward Ultrasound Molecular Imaging with Phase-Change Contrast Agents: An In-Vitro Proof-of-Principle. Ultrasound Med Biol.; in press.
55. Dayton PA, Pearson D, Clark J, et al. Ultrasonic analysis of peptide- and antibody-targeted microbubble contrast agents for molecular imaging of avß3-expressing cells. Mol Imaging 2004; 3: v125-34.
56. Kang S-T, Yeh C-K. Intracellular Acoustic Droplet Vaporization in a Single Peritoneal Macrophage for Drug Delivery Applications. Langmuir 2011; 37: 13183-8.
57. Wang HY, Chen JX, Sun YX, et al. Construction of cell penetrating peptide vectors with N-terminal stearylated nuclear localization signal for targeted delivery of DNA into the cell nuclei. J Control Release. 2011; 155: 26-33.
58. Wang HY, Li C, Yi WJ, et al. Targeted delivery in breast cancer cells via iodine: nuclear localization sequence conjugate. Bioconj Chem. 2011; 22: 1567-75.
59. Zhou Y, Yang K, Gao S, et al. Controlled permeation of cell membrane by single bubble acoustic cavitation. J Contr Rel. 2012; 157: 103-11.
60. Xie F, Slikkerveer J, Gao S et al. Coronary and microvascular thrombolysis with guided diagnostic ultrasound and microbubbles in acute ST segment elevation myocardial infarction. J Am Soc Echocardiogr. 2011; 24: 1400-8.
61. Hennings LJ, Flores R, Roberson PK, et al. Persistent Penumbra in a Rabbit Stroke Model: Persistence and Histologic Characteristics. Stroke Res Treat. 2011; epub.
62. Alexandrov AV, Mikulik R, Ribo M, et al. A Pilot Randomized Clinical Safety Study of Sonothrombolysis Augmentation With Ultrasound- Activated Perflutren-Lipid Microspheres for Acute Ischemic Stroke. Stroke. 2008; 39: 1464-9.
63. Wisner, ER, Ferrara, KW, Short RE et al. Sentinel Node Detection using Contrast-Enhanced Power Doppler Ultrasound Lymphography. Invest Radiol. 2003; 38(6): 358-365.
64. Goldberg, BB, Merton, DA, Liu, J-B et al. Contrast-Enhanced Ultrasound Imaging of Sentinel Lymph Nodes After Peritumoral Administration of Sonazoid in a Melanoma Tumor Animal Model. J Ultrasound Med. 2011; 30: 441-53.
65. Goldberg BB, Merton DA, Liu JB, et al. Contrast-enhanced sonographic imaging of lymphatic channels and sentinel lymph nodes. Ultrasound Med Biol. 2005; 24: 953-65.
66. Kawai Y, Aijima K, Nagai T, et al. Real-time imaging of the lymphatic channels and sentinel lymph nodes of the stomach using contrast- enhanced ultrasonography with Sonazoid in a porcine model. Cancer Sci. 2011; 102: 2073-81.
67. Klapman J, Chang KJ, Wiersema M, et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy in esophageal cancer. Endoscopy Apr 2005; 37: 381-5.
68. Lambert R, Caletti G, Cho E, et al. International Workshop on the clinical impact of endoscopic ultrasound in gastroenterology. Endoscopy. 2000; 32: 549-84.
69. Kahaleh M, Shami VM, Conaway MR, et al. Endoscopic ultrasound drainage of pancreatic pseudocyst: a prospective comparison with conventional endoscopic drainage. Endoscopy. 2006; 38: 355-9.
70. Caletti G, Fusaroli P. The rediscovery of endoscopic ultrasound (EUS) in gastric cancer staging. Endoscopy 2012; 44: 553-5.
71. Shaheen NJ. Advances in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 2005; 128: 1554-66.
72. Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004; 127: 310-30.
73. Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology. 2011; 140: 1084-91.
74. Chatelain D, Flejou JF. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins. Virchows Arch. 2003; 442: 18-24.
75. Li M, Anastassiades CP, Joshi B, et al. Affinity peptide for targeted detection of dysplasia in Barrett's esophagus. Gastroenterology 2010; 139: 1472-80.
76. Goetz M, Wang TD. Molecular imaging in gastrointestinal endoscopy. Gastroenterology. 2010; 138: 828-33.
77. Bulsiewicz WJ, Shaheen NJ. The role of radiofrequency ablation in the management of Barrett's esophagus. Gastrointest Endosc Clin N Am. 2011; 21: 95-109.
78. Crawford HC, Scoggins CR, Washington MK, et al. Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J Clin Invest. 2002; 109: 1437-44.
79. Nichols LS, Ashfaq R, Iacobuzio-Donahue CA. Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. American journal of clinical pathology. 2004; 121: 226-30.
80. Raut CP, Tseng JF, Sun CC, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007; 246: 52-60.
81. Rapoport NY, Nam KH, Gao Z et al. Application of Ultrasound for Targeted Nanotherapy of Malignant Tumors. Acoust Phys. 2009; 55: 594-601.
82. Fabiilli ML, Haworth KJ, Sebastian IE et al. Delivery of chlorambucil using an acoustically-triggered perfluoropentane emulsion. Ultrasound Med Biol. 2010; 36: 1364-75.